Аннотация:Introduction: At the moment, the most relevant is a personalized approach to the therapy of mental disorders. The method of pharmacogenetic tests to assess the effectiveness and safety of psychotropic therapy is widely used.Objectives: To study the use of pharmacogenetic test in clinical practice for the selection of effective and safe psychotropic therapy.Methods: The developed algorithm is based on the PharmGKB database information on the effect of genetic polymorphisms on the efficacy and safety of drugs. Only associations with evidence level 2B and above and confirmed in the European population were taken into account. The peculiarity of the test is to take into account the cumulative contribution of several associated genetic markers. High-density Illumina biochips were used as a genotyping method. The pharmacogenetic test was tested on patients of the Mental Hospital №1 named after N. A. Alexeev, Moscow, Russia.Results: The developed test was tested on 25 patients with various mental disorders. This paper presents the results for the following SNP gene ANKK1, DRD 2 rs1800497, htr2c gene rs 1414334, MC4R gene rs 489693, CYP2D6 gene rs 3892097, CYP2C19 gene *1, *17, *2, *3, *4, indicating the efficacy and safety of drugs. After correction of therapy, depending on the test results, remission was achieved in all cases. Catamnesis for more than 6 months.Conclusions: The use of pharmacogenetic test allows you to accurately predict the reaction of the body to treatment with psychotropic drugs and significantly reduce the time for the selection of optimal therapy.Conflict of interest: No